Metsera (MTSR) Presented at the 85th Scientific Sessions of the American Diabetes Association

Metsera, Inc. (NASDAQ:MTSR) is one of the 11 Hot New Stocks to Invest in Now. On June 22, Metsera, Inc. (NASDAQ:MTSR) presented at the 85th Scientific Sessions of the American Diabetes Association. The company had announced its presentation plan earlier on June 5.

The company showcased its portfolio of therapies, including ultra-long-acting, scalable, and combinable treatments. The main focus was on their lead program, MET-097i, which is a fully biased, monthly, ultra-long acting GLP-1 receptor agonist. Metsera, Inc. (NASDAQ:MTSR) shared clinical data from its Phase 1/2 trial, including body weight changes and tolerability after weekly and monthly doses. Moreover, Metsera, Inc. (NASDAQ:MTSR) also showcased preclinical data on MET-233i, which is an ultra-long-acting amylin analog designed for monthly use.

Metsera, Inc. (NASDAQ:MTSR) is a clinical-stage biopharmaceutical company that focuses on new medicines for obesity and metabolic diseases.

While we acknowledge the potential of MTSR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.